Tellingly, LipC6 in combination with anti‐CTLA4 antibody, but not anti‐PD‐1 antibody, significantly slowed tumor growth, enhanced tumor‐infiltrating CD8+ T cells, and suppressed tumor‐resident Tregs, representing a novel therapeutic approach with significant potential in activating anti-tumor immune response 133. Here, CD8A is linked to neoplasm.